Italia markets closed

Emergent BioSolutions Inc. (0IGA.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
33,40-4,76 (-12,48%)
Alla chiusura: 04:25PM BST
Schermo intero
Chiusura precedente38,15
Aperto33,63
Denaro0,00 x N/D
Lettera0,00 x N/D
Min-Max giorno33,40 - 33,63
Intervallo di 52 settimane33,40 - 33,63
Volume250
Media VolumeN/D
Capitalizzazione1,475B
Beta (5 anni mensile)0,98
Rapporto PE (ttm)11,26
EPS (ttm)2,97
Prossima data utili27 lug 2022 - 01 ago 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Emergent BioSolutions to Acquire from Chimerix its Exclusive Worldwide Rights to TEMBEXA® (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All Ages

    Expands and further diversifies Emergent’s medical countermeasures portfolio with the addition of a small molecule therapeutic addressing a high priority public health threatTransaction to be funded with currently available funds; Expected to be accretive beginning with anticipated product deliveries to the U.S. government in 2022 GAITHERSBURG, Md., May 16, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into a definitive agreement with Chimeri

  • GlobeNewswire

    Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 26, 2022 at 9:00am EDT

    GAITHERSBURG, Md., May 12, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that its 2022 Annual Meeting of Stockholders will be held in a virtual-only format via live audio webcast on Thursday, May 26, 2022 at 9:00 AM EDT. HOW TO PARTICIPATE IN THE VIRTUAL ANNUAL MEETINGAs described in the proxy materials, stockholders of record are eligible to participate in and ask questions during the Virtual Annual Meeting by visiting www.virtualshareholdermeeting.com/EBS2022

  • GlobeNewswire

    Emergent BioSolutions Reports Financial Results For First Quarter 2022

    Reports Q1 2022 total revenues of $308M, in line with guidance, and Adjusted EBITDA of $36MTemporarily suspends CDMO guidance pending further clarity on COVID-19 vaccine requirements GAITHERSBURG, Md., April 28, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the first quarter ended March 31, 2022. “Emergent remains focused on our strategic plan to grow within public health threat markets where we can positively impact patients and customers,”